Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer

British Journal of Surgery

Volumn 87, Issue 8, 2000, Pages 1006-1015

  Ceelen, W P ^a   Hesse, U ^a   De Hemptinne, B ^a   Pattyn, P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 1ALPHA; IRINOTECAN; LOBAPLATIN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TUMOR NECROSIS FACTOR; VINBLASTINE;

ABDOMINAL CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; HUMAN; HYPERTHERMIC THERAPY; MEDICAL LITERATURE; META ANALYSIS; MORBIDITY; MORTALITY; PERITONEUM; PRIORITY JOURNAL; STOMACH CANCER; TECHNIQUE;

ABDOMINAL NEOPLASMS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SARCOMA; STOMACH NEOPLASMS;

EID: 0033931247     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01538.x     Document Type: Article

References (105)

1. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994; 81: 7-19.
2. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-7.
3. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 1999; 26: 536-9.
4. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 256-60.
5. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci 1893; 105: 487-511.
6. Arancia G, Crateri Trovalusci P, Mariutti G, Mondovi B. Ultrastructural changes induced by hyperthermia in Chinese hamster V79 fibroblasts. Int J Hyperthermia 1989; 5: 341-50.
7. Hahn GM, Shiu EC. Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res 1983; 43: 5789-91.
8. Lepock JR. Involvement of membranes in cellular responses to hyperthermia. Radiat Res 1982; 92: 433-8.
9. Gnant MFX, Noll LA, Terrill RE, Wu PC, Berger AC, Nguyen HQ et al. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery 1999; 126: 890-9.
10. Calderwood SK, Hahn GM. Thermal sensitivity and resistance of insulin-receptor binding. Biochim Biophys Acta 1983; 756: 1-8.
11. Armour EP, McEachern D, Wang Z, Corry PM, Martinez A. Sensitivity of human cells to mild hyperthermia. Cancer Res 1993; 53: 2740-4.
12. Hahn GM. Hyperthermia and Cancer. New York: Plenum, 1982.
13. Reed RA, Bedford JS. Thermal tolerance. Br J Radiol 1980; 53: 920-1 (Letter).
14. Hahn GM, van Kersen I. Isolation and initial characterization of thermoresistant RIF tumor cell strains. Cancer Res 1988; 48: 1803-7.
15. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998; 41: 147-54.
16. Pestieau SR, Stuart OA, Chang D, Jacquet P, Sugarbaker PH. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998; 84: 706-11.
17. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997; 80: 2084-90.
18. Van Goethem AR, Beijnen JH, Van Coevorden F, Kaag MM, Van Slooten GW, Zoetmulder FAN. Cytoreductie en hypertherme intraperitoneale chemotherapie. Ned Tijdschr Heelk 1997; 6: 107-11.
19. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979; 39: 2264-8.
20. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992; 52: 487-90.
21. Stein U, Rau B, Wust P, Walther W, Schlag PM. Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression. Int J Cancer 1999; 80: 5-12.
22. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981; 41: 1096-9.
23. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 1998; 55: 130-8.
24. Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY et al. Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 1993; 50: 366-70.
25. Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ et al. Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1993; 11: 1787-94.
26. Rietbroek RC, van de Vaart PJM, Haveman J, Blommaert FA, Geerdink A, Bakker PJM et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123: 6-12.
27. Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J et al. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 1991; 51: 2994-3000.
28. Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27: 472-7.
29. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994; 69: 235-41.
30. Masuda H, Tanaka T, Matsushima S. Hyperthermic enhancement of cisplatin-induced generation of active oxygen radicals in a cell-free system. Anticancer Res 1998; 18: 1473-7.
31. Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia - a review. Int J Hyperthermia 1997; 13: 439-57.
32. Raaphorst GP, Doja S, Davis L, Stewart D, Ng CE. A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment. Cancer Chemother Pharmacol 1996; 37: 574-80.
33. Yamauchi N, Watanabe N, Maeda M, Okamoto T, Sasaki H, Tsuji N et al. Mechanism of synergistic cytotoxic effect between tumor necrosis factor and hyperthermia. Jpn J Cancer Res 1992; 83: 540-5.
34. Hachiya T, Okada K, Sakurai A, Satomi N, Haranaka K. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia against heterotransplanted human prostatic carcinoma and its lymph node metastasis in nude mice. Mol Biother 1992; 4: 34-9.
35. Song CW, Lin JC, Lyons JC. Antitumor effect of interleukin 1α in combination with hyperthermia. Cancer Res 1993; 53: 324-8.
36. Ikeda S, Akagi K, Shiraishi T, Tanaka Y. Enhancement of the effect of an angiogenesis inhibitor on murine tumors by hyperthermia. Oncol Rep 1998; 5: 181-4.
37. Dogramatzis D, Nishikawa K, Newman RA. Interaction of hyperthermia with bleomycin and liblomycin: effects on CHO cells in vitro. Anticancer Res 1991; 11: 1359-64.
38. Katschinski DM, Robins HI. Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity. Int J Cancer 1999; 80: 104-9.
39. Kutz ME, Mulkerin DL, Wiedemann GJ, Katschinski DM, Robins HI. In vitro studies of the hyperthermic enhancement of activated ifosfamide (4-hydroperoxy-ifosfamide) and glucose isophosphoramide mustard. Cancer Chemother Pharmacol 1997; 40: 167-71.
40. Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJM. Effect of hyperthermia on the cytotoxicity of 2′-2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995; 62: 627-30.
41. Dumontet C, Bodin F, Michal Y. Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistance. Clin Cancer Res 1998; 4: 1563-6.
42. Overgaard J, Gonzalez-Gonzalez D, Hulshof MCCM, Arcangeli G, Dahl O, Mella O et al. Randomized trial of hyperthermia as adjuvant to radiotherapy to recurrent or metastatic malignant melanoma. Lancet 1995; 345: 540-3.
43. Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer - results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35: 731-44.
44. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 535-49.
45. Shakil A, Osborn JL, Song CW. Changes in oxygenation status and blood flow in a rat tumor model by mild temperature hyperthermia. Int J Radiat Oncol Biol Phys 1999; 43: 859-65.
46. Zywietz F, Reeker W, Kochs E. Changes in tumor oxygenation during a combined treatment with fractionated irradiation and hyperthermia: an experimental study. Int J Radiat Oncol Biol Phys 1997; 37: 155-62.
47. Seegenschmiedt MH, Martus P, Fietkau R, Iro H, Brady LW, Sauer R. Multivariate analysis of prognostic parameters using interstitial thermoradiotherapy (IHT-IRT): tumor and treatment variables predict outcome. Int J Radiat Oncol Biol Phys 1994; 29: 1049-63.
48. 3 (TNM-UICC) neck nodes: a prospective randomized clinical trial. Int J Radiat Oncol Biol Phys 1988; 15: 13-24.
49. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345: 540-3.
50. Oldhafer KJ, Frerker MK, Lang H, Fauler J, Flemming P, Schmoll E et al. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. J Invest Surg 1998; 11: 393-400.
51. Walther MM, Jennings SB, Choyke PL, Andrich M, Hurley K, Linehan WM et al. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol 1996; 14(Suppl 1): S2-7.
52. Koops HS, Vaglini M, Suciu S, Kroon BBR, Thompson JF, Gohl J et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906-12.
53. Plaat BE, Molenaar WM, Mastik MF, Koudstaal J, van den Berg E, Koops HS et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res 1999; 5: 1650-7.
54. Johnston MR, Minchen RF, Dawson CA. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995; 110: 368-73.
55. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999; 43: 1111-23.
56. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-32.
57. Kuzu M, Koksoy C, Kale T, Demirpence E, Renda N. Experimental study of the effect of preoperative 5-fluorouracil on the integrity of colon anastomoses. Br J Surg 1998; 85: 236-9.
58. Fumagalli U, Trabucchi E, Soligo M, Rosati R, Rebuffat C, Tonelli C et al. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Surg Res 1991; 50: 82-7.
59. Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg 1991; 78: 57-9.
60. Biert J, Seifert W, de Man B, Wobbes T, Hoogenhout J, Hendriks T. Combined preoperative irradiation and local hyperthermia delays early healing of experimental colonic anastomoses. Arch Surg 1996; 131: 1037-42.
61. Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77: 2622-39.
62. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-34.
63. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
64. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
65. Markman M, Bundy B, Benda J, Alberts D, Wadler S, Fowler J, Clark-Pearson D, Carson LF, for the Gynecologic Oncology Group, Buffalo, NY. Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): an intergroup trial (GOG, SWOG, ECOG). Proceedings of the American Society of Clinical Oncology 1998; 17: A-1392, 361a.
66. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995; 13: 2961-7.
67. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620-4.
68. Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990; 26: 755-62.
69. Zakris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 1987; 5: 1613-20.
70. Buell JF, Bartlett DL, Venson DJ. Continuous hyperthermic peritoneal perfusion (CHPP) with TNF and cisplatin for the treatment of peritoneal carcinomatosis. Society of Surgical Oncology 49th Annual Meeting, Atlanta, GA, USA, 1996 (Abstract 77).
71. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43: 106-14.
72. van de Vaart PJM, van der Vange N, Zoetmulder FAN, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: 148-54.
73. Formenti SC, Shrivastava PN, Sapozink MS, Jozsef G, Chan KK, Jeffers S et al. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology. Int J Radiat Oncol Biol Phys 1996; 35: 993-1001.
74. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999; 340: 908-14.
75. 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-30.
76. Juhl H, Stritzel M, Wroblewski A, Henne-Bruns D, Kremer B, Schmiegel W et al. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57: 330-5.
77. Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60-4.
78. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994; 73: 2048-52.
79. Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, Fujimura K, Sawa T et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 1995; 19: 450-5.
80. Kim JY. Changing recurrent patterns after surgery plus intraperitoneal hyperthermo chemoperfusion in stage III gastric cancer patients. WHO-CC for Gastric Cancer. 12th International Seminar. Seoul, Korea. 1996: 146.
81. Sayag-Beaujard AC, Francois Y, Glehen O, Sadeghi-Looyeh B, Bienvenu J, Panteix G et al. Intraperitoneal chemohyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res 1999; 19: 1375-82.
82. Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum 1991; 34: 723-7.
83. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-60.
84. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43(Suppl): S15-25.
85. Scheithauer W, Kornek GV, Marczell A, Karner J, Salem G, Greiner R et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998; 77: 1349-54.
86. Fujimoto S, Takahashi M, Endoh F, Shrestha RD, Kokubun M, Takai M et al. A clinical pilot study combining surgery with intraoperative pelvic hyperthermochemotherapy to prevent the local recurrence of rectal cancer. Ann Surg 1991; 213: 43-7.
87. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124-32.
88. Yonemura Y, Fujimura T, Fushida S, Fujita H, Bando E, Nishimura G et al. A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. Hepatogastroenterology 1999; 46: 601-9.
89. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 1999; 39: 394-401.
90. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83: 1251-61.
91. Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 1997; 3: 174-9.
92. Stephens AD, Belliveau JF, Sugarbaker PH. Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. In: Sugarbaker P, ed. Peritoneal Carcinomatosis: Drugs and Diseases. Boston, Massachusetts: Kluwer Academic Publishers, 1996: 15-30.
93. Kober F, Heiss A, Roka R. Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. In: Sugarbaker P, ed. Peritoneal Carcinomatosis: Drugs and Diseases. Boston, Massachusetts: Kluwer Academic Publishers, 1996: 211-19.
94. Loggie BW, Perini M, Fleming RA, Russell GB, Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997; 63: 137-43.
95. Mansvelt B, Bertrand C, Nockerman P, Arnould P, Delvaux P, Lechien X et al. Study of the toxicity and results of intraperitoneal hyperthermic chemotherapy in 28 patients with peritoneal carcinomatosis. Ann Chir 1997; 51: 60-7.
96. Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 1999; 84: 60-6.
97. Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y et al. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study. Anticancer Res 1999; 19: 2317-21.
98. Jähne J, Piso P. Peritonektomie und intraperitoneale Chemotherapie-Neue Wege zur multimodalen Therapie der Peritonealkarzinose. Langenbecks Arch Chir Suppl 1998; 115: 1435-7.
99. Sugarbaker PH. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994; 37(Suppl 2): S115-22.
100. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
101. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14: 254-61.
102. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23: 23-9.
103. Zoetmulder FA, van der Vange N, Witkamp AJ, Kaag MM, Boot H, Beijnen JH. Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute. Ned Tijdschr Geneesk 1999; 143: 1863-8.
104. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845-51.
105. Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6: 582-90.